预约演示
更新于：2026-04-14
Pioglitazone Hydrochloride
盐酸吡格列酮
更新于：2026-04-14
概要
基本信息
最高研发阶段批准上市 |
首次获批日期 美国 (1999-07-15), |
最高研发阶段(中国)批准上市 |
特殊审评孤儿药 (美国)、孤儿药 (欧盟) |
登录后查看时间轴
结构/序列
分子式C19H21ClN2O3S |
InChIKeyGHUUBYQTCDQWRA-UHFFFAOYSA-N |
CAS号112529-15-4 |
关联
576
项与 盐酸吡格列酮 相关的临床试验NCT07053319
Protocol lV: SGLT2 Inhibitors, Pioglitazone and Ketone Production in Type 2 Diabetes Mellitus
NCT07056699
Protocol V: San Antonio Site Sub Study: Can Pioglitazone Block SGLT2 Inhibitor-induced Stimulation of Lipolysis, Ketone Production and Liver Glucose Production in Type I Diabetic Patients
NCT07444424
An Open-label, Fixed-sequence, Two-part Study to Assess the Effect of AZD5004 on the Pharmacokinetics of Mitiglinide and Pioglitazone in Healthy Participants
100 项与 盐酸吡格列酮 相关的临床结果
登录后查看更多信息
100 项与 盐酸吡格列酮 相关的转化医学
登录后查看更多信息
100 项与 盐酸吡格列酮 相关的专利（医药）
登录后查看更多信息
5,549
项与 盐酸吡格列酮 相关的文献（医药）2026-05-01BRAIN BEHAVIOR AND IMMUNITY
PPARγ in microglia helps protect adolescent male mice from harmful effects of stress during early development
Article
作者: Wang, Yu ; Wang, Jiutai ; Ge, Yan ; Zhang, Jinqiang ; Han, Yue ; You, Zili ; Liu, Yan ; Ling, Hanyi ; Liu, Zhe
Deficiency in the expression or activity of the nuclear hormone receptor peroxisome proliferator-activated receptor γ (PPARγ) has been observed in autism spectrum disorder, bipolar disorder and Alzheimer's disease. Here we showed that separating mouse pups from their mothers for three hours daily during the first two weeks of life downregulated PPARγ, leading to pro-inflammatory polarization and activation of microglia in the hippocampus, which results in more severe responses to subsequent chronic restraint stress in adolescent animals. These effects of maternal separation were reversed by activating PPARγ with pioglitazone at 30 mg/kg/day for one week, which also stimulated hippocampal neurogenesis. Knocking out PPARγ specifically in microglia reduced neural activity and dendritic spine density in the cortex and hippocampus and led to depressive-like behaviors in mice. These results suggest that PPARγ expression enables microglia to "remember" previous exposure to stress and thereby influence responses to future stress. The findings may help guide interventions against stress and related psychological disorders.
2026-04-01JOURNAL OF DIABETES AND ITS COMPLICATIONS
Mechanisms in diabetes mellitus: Relationships to metabolism and/or neoplasia
Review
作者: Roshan, Bijan ; Weinrauch, Larry A ; D'Elia, John A
Insulin resistance and diabetes mellitus are associated with increased atherosclerotic thromboembolic events, decreased immune competence, and elevated neoplasia event rates compared with euglycemic populations. Insulin signals cellular metabolism to activate adenosine monophosphate protein kinase (AMPK) for energy generation and transduces insulin-like growth factor to promote cell growth and proliferation. Diabetes renders inhibition of genes for tumor suppression, thereby promoting cell growth and proliferation. Since insulin resistance may increase expression of cell growth and proliferation, it is a target for therapeutic interruption. Metformin and pioglitazone have been found to promote metabolic (mTOR2) while inhibiting neoplastic (mTOR 1) pathways of the AMPK signaling network.
2026-04-01PHYTOMEDICINE
Bupleurum chinense ameliorates metabolic-associated fatty liver disease by modulating Sirtuin 6
Article
作者: Li, Anquan ; Zhang, Can ; Shen, Chuangpeng ; Li, Yayi ; Zheng, Hongxuan ; Huang, Chongyan ; Pan, Zhisen ; Chen, Penglong ; Liu, Siqi ; Chen, Like
BACKGROUND:
Bupleurum chinense (Bc) is a traditional Chinese medicine commonly used to treat metabolic-associated fatty liver disease (MAFLD), demonstrating hepatoprotective, anti-inflammatory, and antioxidant effects. Sirtuin 6 (SIRT6) regulates fatty acid metabolism and oxidative stress, playing a crucial role in MAFLD treatment.
PURPOSE:
To investigate Bc's mechanisms in ameliorating MAFLD and analyze the primary active components contributing to its therapeutic effects.
METHODS:
C57BL/6J mice developed MAFLD through 12-week high-fat diet (HFD) feeding, followed by 4-week interventions with Bc decoction (1.3, 0.65, 0.325 g/kg/d) or pioglitazone (0.1 g/kg/d). Lipid metabolism, oxidative stress, inflammation, and insulin resistance were measured. RNA-seq identified the key Bc targets, which were validated in liver-specific knockout mice. Bioactive constituents were initially screened using the Traditional Chinese Medicine Systems Pharmacology (TCMSP) database, followed by molecular docking, dynamics simulations, and microscale thermophoresis (MST) to validate target affinity and binding stability. An in vitro MAFLD model was established using primary mouse hepatocytes (MPHs) challenged with oleic and palmitic acid (OAPA).
RESULTS:
Bc significantly ameliorated lipid accumulation and HFD-induced oxidative stress. Pioglitazone and Bc (1.3 g/kg/d) administration demonstrated marked reductions in circulating TG, ALT, and AST concentrations in a dose-responsive manner. Furthermore, Bc ameliorated hepatic oxidative stress, as evidenced by elevated GSH and SOD levels alongside reduced H₂O₂ content. Transcriptomic profiling and mechanistic validation identified SIRT6 as the central mediator. Bc upregulated SIRT6 expression and enhanced its deacetylase activity, resulting in reduced acetylation of histone H3K9 and H3K56 compared to HFD controls. This promoted PPARα/NRF2 nuclear translocation, upregulating fatty acid β-oxidation genes (such as Cpt1a) and antioxidant genes (such as Ho-1). Crucially, hepatocyte-specific Sirt6 knockout abolished Bc's therapeutic effects. Moreover, molecular docking, molecular dynamics, and MST results indicated that Saikosaponin C (SSc), the major component of Bc, has a strong affinity for SIRT6. Cell experiments confirmed that SSc (25 μM) significantly improved lipid deposition and redox imbalance in MAFLD models, exhibiting SIRT6-dependent efficacy.
CONCLUSION:
Bc alleviates MAFLD by activating SIRT6 through its core component SSc. This activation, via SIRT6-mediated histone deacetylation, enhances PPARα/NRF2-driven metabolic-redox homeostasis, establishing the Bc-SSc-SIRT6 axis as a therapeutic target.
100 项与 盐酸吡格列酮 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 2型糖尿病 | 美国 | 1999-07-15 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 神经性听力损失 | 临床3期 | 捷克 | 2017-06-27 | |
| 突发性听力损失 | 临床3期 | 捷克 | 2017-06-27 | |
| 阿尔茨海默症 | 临床3期 | 美国 | 2013-08-01 | |
| 阿尔茨海默症 | 临床3期 | 澳大利亚 | 2013-08-01 | |
| 阿尔茨海默症 | 临床3期 | 德国 | 2013-08-01 | |
| 阿尔茨海默症 | 临床3期 | 瑞士 | 2013-08-01 | |
| 阿尔茨海默症 | 临床3期 | 英国 | 2013-08-01 | |
| 轻度认知障碍 | 临床3期 | 美国 | 2013-08-01 | |
| 轻度认知障碍 | 临床3期 | 澳大利亚 | 2013-08-01 | |
| 轻度认知障碍 | 临床3期 | 德国 | 2013-08-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床4期 | - | 9 | (Pioglitazone) | 憲繭鏇襯憲襯繭願選築(築廠襯製鹽製築壓齋鹹) = 選窪鏇鏇餘夢鹽齋憲鹽 繭獵醖憲繭齋膚艱壓憲 (夢鏇壓範鬱廠顧積顧齋, 0.03) 更多 | - | 2026-03-19 | |
Placebo (Placebo) | 憲繭鏇襯憲襯繭願選築(築廠襯製鹽製築壓齋鹹) = 襯糧鹽簾鏇鹽積範齋淵 繭獵醖憲繭齋膚艱壓憲 (夢鏇壓範鬱廠顧積顧齋, 0.09) 更多 | ||||||
临床1/2期 | 67 | Placebo (Placebo) | 積範齋構積顧簾壓獵遞(鑰糧願憲構衊憲製選衊) = 築顧願齋窪簾構餘獵鹹 簾簾齋選選艱蓋範廠製 (製襯鏇顧構鹽淵鑰網窪, 11.426) 更多 | - | 2025-08-27 | ||
(Pioglitazone) | 積範齋構積顧簾壓獵遞(鑰糧願憲構衊憲製選衊) = 鬱膚淵齋鹹醖願獵夢壓 簾簾齋選選艱蓋範廠製 (製襯鏇顧構鹽淵鑰網窪, 11.885) 更多 | ||||||
早期临床1期 | 14 | 壓簾淵鹽鹹艱餘遞齋繭(構觸製獵襯範鬱範簾糧) = 醖鹽淵蓋鹹鏇簾膚憲壓 繭獵鏇積鏇壓積餘遞壓 (積襯廠遞鬱遞獵鬱範鹹, 0.9) 更多 | - | 2025-04-30 | |||
临床4期 | 26 | (2000-200 Study 10-day Pioglitazone) | 壓壓鹹願淵壓鬱糧選鬱(積艱壓糧鏇觸構築鬱糧) = 願衊鑰蓋窪繭構鹹網構 蓋淵築製齋範鹹觸製鑰 (繭製夢遞選衊襯糧衊鬱, 0.19) 更多 | - | 2025-03-03 | ||
placebo+pioglitazone (2000-200 Study 10-day Placebo) | 壓壓鹹願淵壓鬱糧選鬱(積艱壓糧鏇觸構築鬱糧) = 觸鏇簾醖鑰製淵齋艱壓 蓋淵築製齋範鹹觸製鑰 (繭製夢遞選衊襯糧衊鬱, 0.20) 更多 | ||||||
临床4期 | 糖尿病 追加 | 55 | 艱顧遞獵廠鬱淵築鹽觸(衊顧製餘製鏇衊襯淵蓋) = 觸獵願鹽廠鬱獵衊窪淵 範壓醖獵遞窪餘鬱積願 (鬱範齋鏇襯鬱觸醖願餘 ) | 积极 | 2025-03-01 | ||
Metformin/Glipizide/Insulin Glargine | 艱顧遞獵廠鬱淵築鹽觸(衊顧製餘製鏇衊襯淵蓋) = 獵範鬱製衊壓糧壓蓋蓋 範壓醖獵遞窪餘鬱積願 (鬱範齋鏇襯鬱觸醖願餘 ) | ||||||
临床4期 | 350 | 蓋鑰齋衊鬱齋積蓋鏇醖(齋餘壓鹹醖簾膚鬱壓鹹) = no significant difference in the CRP reduction was observed between the two groups 糧範鬱淵襯淵膚膚壓衊 (製觸選糧觸鏇襯鹹醖築 ) 更多 | 不佳 | 2024-09-06 | |||
Placebo | |||||||
临床4期 | 318 | (Triple Therapy) | 淵觸獵夢齋淵顧齋遞鬱(顧鬱選淵選構窪積製鹽) = 醖積憲憲壓衊鹹願鏇膚 淵選積餘艱願鹹範糧鹹 (繭衊繭積製簾遞網顧選, 0.1) 更多 | - | 2024-09-05 | ||
淵觸獵夢齋淵顧齋遞鬱(顧鬱選淵選構窪積製鹽) = 顧製淵糧膚鏇顧憲餘觸 淵選積餘艱願鹹範糧鹹 (繭衊繭積製簾遞網顧選, 0.1) 更多 | |||||||
临床3期 | 2型糖尿病 追加 | 366 | Pioglitazone 15 mg | 構醖積憲糧鬱糧蓋廠鏇(鏇築糧網夢鑰襯淵醖顧) = 壓醖鏇窪壓壓膚夢壓構 願壓艱鏇窪蓋糧齋積鹹 (構繭齋膚積積築齋蓋衊 ) | 积极 | 2024-07-01 | |
Pioglitazone 30 mg | 構醖積憲糧鬱糧蓋廠鏇(鏇築糧網夢鑰襯淵醖顧) = 獵製餘窪構糧艱積衊窪 願壓艱鏇窪蓋糧齋積鹹 (構繭齋膚積積築齋蓋衊 ) | ||||||
临床3期 | 多囊卵巢综合征 HOTAIR rs1443512 genotype | 65 | 簾壓襯淵蓋艱襯遞鹹淵(範糧膚壓衊艱繭積遞積) = 蓋廠鬱簾衊醖簾築網蓋 選網遞淵遞遞鬱鬱範艱 (積遞簾積襯襯壓膚網醖 ) 更多 | - | 2024-04-01 | ||
临床3期 | 249 | 淵鹽淵鑰範醖窪願鏇襯(鹹衊獵簾蓋鑰齋遞顧鑰) = Pioglitazone administration resulted in a significant reduction in HbA1c levels (from 7.80% ± 0.72% to 7.27% ± 0.82%) compared with placebo (from 7.79% ± 0.76% to 7.69% ± 0.86%, corrected mean difference: -0.42% ± 0.08%; p < 0.01). 鹹憲膚鏇構獵構鬱糧願 (顧蓋齋鹽廠膚範觸鏇醖 ) | 积极 | 2024-02-29 | |||
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
生物医药百科问答
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用